Sanmina stock reaction to new LIBERTY System manufacturing deal

Sanmina (SANM) stock moved after Microbot Medical selected the company to manufacture its FDA cleared LIBERTY Endovascular Robotic System, giving Sanmina a new contract in the medical device manufacturing segment.

Alongside this Microbot Medical agreement, Sanmina has shifted into larger equity benchmarks such as the Russell 1000 and Russell Midcap indices. Despite a 1-day share price return of 2.64% and 1-month share price return of 6.98% in the red, its 1-year total shareholder return of 143.37% and 5-year total shareholder return of more than 5x indicate strong momentum over longer periods.

If this kind of contract-driven story has your attention, it can be useful to see what else is moving in related areas through a curated robotics and automation stock list such as the 29 robotics and automation stocks.

With Sanmina now trading around US$246 and sitting above both its analyst price target and an estimated intrinsic value, the big question is whether investors are looking at an overstretched stock or one still pricing in future growth.

Most Popular Narrative: 10.1% Overvalued

Sanmina's most followed narrative puts fair value at $223.75, which sits below the last close of $246.39 and frames the current premium in context.

The imminent acquisition of ZT Systems is expected to add $5–6 billion of annual run-rate revenue, positioning Sanmina to double its net revenue within three years and capitalize on explosive growth in data center and AI infrastructure investment; this should provide a multi-year boost to overall revenue and EPS accretion from synergies and integration.

Want to understand why this narrative still lands below the current share price? Revenue expansion, slimmer margins, and a richer future earnings multiple sit at the core.

Result: Fair Value of $223.75 (OVERVALUED)

However, Sanmina still faces real pressure points, including high customer concentration as well as the execution and inventory risks tied to the planned ZT Systems acquisition.

Next Steps

Mixed signals around Sanmina's upside and risks can feel hard to balance. Take a moment to review the data yourself and pressure test both sides of the story with the 1 key reward and 2 important warning signs

Looking for more investment ideas beyond Sanmina?

If Sanmina has sharpened your focus, now is a good moment to widen the lens and spot other opportunities that fit your style before the crowd does.

• Target resilience first by checking companies in the 73 resilient stocks with low risk scores that may better align with your comfort level when markets get choppy.
• Hunt for quality at a potential discount through the 41 high quality undervalued stocks and see which stocks currently look attractively priced on fundamentals.
• Build a watchlist of potential early movers using the screener containing 19 high quality undiscovered gems before they sit firmly on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.